Depot Formulation Bioavailability

Depot formulation bioavailability characterises pharmaceutical absorption from intramuscular or subcutaneous reservoirs determining therapeutic efficacy. Microcrystalline suspension formulations exhibit complex dissolution and diffusion kinetics. Polymer microsphere systems produce biphasic release with initial burst followed by sustained kinetics. Oil-based depots form biocompatible matrices controlling drug release.

Compare release studies correlate in vitro release profiles with in vivo bioavailability. Formulation variables including drug solubility, polymer composition, and microsphere size substantially influence bioavailability. Regulatory bioequivalence studies compare depot formulations to oral reference formulations. Injection site reactions including sterile abscess formation warrant monitoring. Clinical dosing intervals optimise therapeutic levels throughout dosing period.